Please login to the form below

Not currently logged in
Email:
Password:

Daiichi Sankyo on track for edoxaban filing in 2014

Positive phase III data for anticoagulant

Daiichi Sankyo logo

Daiichi Sankyo is celebrating positive phase III results for its new anticoagulant edoxaban that put the product firmly on course for regulatory filings early next year.

The once-daily, oral Factor Xa inhibitor was shown to be non-inferior to injectable warfarin for treatment and prevention of recurrent symptomatic venous thromboembolism (VTE) in the phase III trial, which was reported at the European Society of Cardiology (ESC) meeting over the weekend.

Importantly edoxaban also outperformed warfarin on the principal safety measure in the study and was significantly less likely to cause clinically-relevant bleeding.

The results - which have simultaneously been published in the New England Journal of Medicine - set Daiichi Sankyo on track to file for approval of edoxaban in VTE by the first quarter of 2014 in the US, Europe and Japan, according to the company's global R&D head Glenn Gormley.

Edoxaban was first approved in Japan in 2011 under the Lixiana brand name for the prevention of VTE in patients undergoing orthopaedic surgeries, and is also in a phase III trial involving atrial fibrillation (AF) patients, with results due later this year.

The results of the phase III Hokusai-VTE study are largely in line with trials of other Factor Xa inhibitors in this setting, notably Pfizer and Bristol-Myers Squibb's twice-daily Eliquis (apixaban) and Bayer's once-daily Xarelto (rivaroxaban), as well as rival drug Pradaxa (dabigatran) from Boehringer Ingelheim which acts as a direct thrombin inhibitor and is given twice a day.

All these drugs have been tipped as potential replacements for warfarin and, with their oral dosing and the fact that they do not require such close dose titration and monitoring making them suitable for out-of-hospital use, could open up a multi-billion dollar market.

Edoxaban will come to the party a little later than its competitors so may struggle to make headway against the established brands. It has, however, been tipped as a $5bn product at peak by some analysts if it can perform as well as expected in the AF setting, proving superior to warfarin in reducing both stroke and systemic embolism and reducing bleeding complications.

Article by
Phil Taylor

2nd September 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....